Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Sage Therapeutics (SAGE) shares have declined 11.1% in the month following its last earnings report, underperforming the S&P 500. While fresh estimates have trended upward, the stock has a Zacks Rank #3 (Hold), suggesting expectations of an in-line return in the near term. The stock receives a Growth Score of B but lags in Momentum and Value, with scores of D.

Analysis

Sage Therapeutics (SAGE) has experienced a notable share price decline of 11.1% in the month following its last earnings report, significantly underperforming the S&P 500. Despite this recent negative performance, fresh analyst estimates for the company have trended upward during the past month. However, the article highlights a nuanced situation, stating that "the magnitude of these revisions indicates a downward shift," suggesting that while estimates have increased, the overall outlook or the degree of positive revision may not be robust enough to signal a strong upward trajectory. The company's investment profile, according to VGM Scores, is mixed: it holds a favorable Growth Score of B, but scores poorly on Momentum (D) and Value (D), placing it in the bottom 40% for the latter. Overall, Sage Therapeutics has an aggregate VGM Score of C and a Zacks Rank #3 (Hold), leading to an expectation of an in-line return from the stock over the next few months.

Key Decisions for Investors

• Given Sage Therapeutics' recent 11.1% share price decline, underperformance relative to the S&P 500, and a Zacks Rank #3 (Hold), investors should exercise caution and consider a neutral stance pending further catalysts.
• Investors should closely monitor upcoming earnings releases and the evolution of analyst estimates, particularly to understand the apparent contradiction between upward trending fresh estimates and the 'downward shift' indicated by their magnitude, before making significant investment decisions.
• The stock's strong Growth Score (B) is offset by weak Momentum (D) and Value (D) scores; therefore, investors prioritizing growth might find some appeal, but those focused on momentum or value strategies should be wary or await improvements in these areas.